



**Research Scholar Award
2005 - 2008**

RESEARCH SCHOLAR AWARDS

Commencing January 2008

Grant Title: The use of cytotoxic T cells for immunotherapy of viral infections post allogeneic stem cell transplantation

Description: Blood stem cell transplantation is a potential cure for blood cancers including leukaemia and lymphoma. After transplant the body's immune system is unable to fight viral infections which often cause serious illness or death in these patients. This research uses immune cells which are taken from the donor, grown in the laboratory and injected into the patient. It is hoped that the immune cells will fight the viruses and improve survival for these patients.

The Grant was awarded to:

- **Dr Emily Blyth**

Administering Institute: Sydney South West Area Health Services

Research Institute: Westmead Millennium Institute

Grant Reference: 07/RSA/1-02

\$75,000 over 3 years

Grant Title: Mechanisms of oncogene induced cellular senescence of primary human melanocytes

Description: NSW figures for 2003 show that Melanoma is the most common cancer in the 15-24 year age group, and the third most common cancer overall. In 2001 over 8500 people were diagnosed with melanoma in Australia and the number of new cases is steadily rising. Melanoma that has spread to distant sites in the body, or to other organs can rarely be cured. These facts highlight the urgent need for better treatment. Precise information regarding altered molecular pathways in melanoma development is highly relevant if rational strategies for prevention and targeted therapy are to be developed and refined.

The Grant was awarded to:

- **Dr Sebastian Haferkamp**

Administering Institute: The University of Sydney

Research Institute: Westmead Institute for Cancer Research

Grant Reference: 07/RSA/1-07

\$25,000 over 1 year

Grant Title: Functional characterisation of IGFBP-5 interactions with SPRY2, RASIP1 and GADD34 in breast cancer cells

Description: Breast cancer is the most common cause of cancer-related deaths in Australian women and it typically eventuates after deregulation of the key regulators of cell growth in normal mammary cells. Breast cancer cells can respond to a number of proteins that influence cell growth regulation. The insulin-like growth factor binding protein 5 (IGFBP-5) has been shown to inhibit the growth of breast cancer cells and recently, SPRY2, RASIP1 and GADD34 were identified as novel IGFBP-5 interacting

proteins. This project aims to further characterise these protein interactions and the subsequent functional consequences in breast cancer cells.

The Grant was awarded to:

- **Miss Penny Ho**

Administering Institute: The University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 07/RSA/1-08

\$50,000 over 1 year

Grant Title: An investigation of the regulation of chromatin structure, a fundamental aspect of cancer initiation and progression.

Description: The onset and development of cancer is associated with changes in how genes are switched on and off – the process known as gene expression. However, we still have only a very incomplete understanding of the mechanisms that control gene expression throughout the body and during development. In my PhD study, I will identify proteins that play important roles in regulating the structure of DNA (and hence regulating gene expression) and determine the molecular basis for their activity. I will also engineer new proteins that can be targeted to specific sites in the genome and therefore potentially be used to manipulate gene expression for research or therapeutic purposes.

The Grant was awarded to:

- **Ms Eija Lehtomaki**

Administering Institute: The University of Sydney
Research Institute: The University of Sydney

Grant Reference: 07/RSA/1-10

\$50,000 over 1 year

Grant Title: Nuclear actions and export of insulin-like growth factor binding protein-3.

Description: Insulin-like growth factor binding protein-3 (IGFBP-3) transports insulin-like growth factors in the bloodstream, but also has independent actions inside cells. Some actions of IGFBP-3 within the nucleus of cancer cells are thought to be important in regulating the growth and survival of these cells. Specific parts of the IGFBP-3 molecule are believed to regulate the transport of IGFBP-3 to and from the nucleus. This project will investigate proteins involved in these nuclear actions of IGFBP-3 in breast cancer cells, and will identify which parts of the IGFBP-3 molecule are involved in transporting IGFBP-3 out of the nucleus.

The Grant was awarded to:

- **Mr Gang Lu**

Administering Institute: The University of Sydney
Research Institute: The University of Sydney

Grant Reference: 07/RSA/1-11

\$75,000 over 3 years commencing April 2008

Grant Title: Epigenetic Mechanisms of Pituitary Tumourigenesis

Description: Clinically relevant pituitary tumours are common, occurring in 1 in every 1388 individuals. Currently, little is known about the cause of pituitary tumours, nor what causes some tumours to become aggressive, invading adjacent vital brain structures and sometimes causing death. Over the last 5 years cancer researchers have come to appreciate the role that alteration in DNA structure (“epigenetics”) has in tumour development. This research project aims to study epigenetic alterations underlying the development and progression of pituitary tumours which may lead to improved treatment for patients with pituitary tumours.

The Grant was awarded to:

- **Dr Ann McCormack**

Administering Institute: The University of Sydney

Research Institute: Kolling Institute of Medical Research

Grant Reference: 07/RSA/1-13

\$37,500 over 6 months

Grant Title: Effect of melanoma-associated p16INK4a mutants on the function of the wild-type protein

Description: Melanoma is one of the most common and deadliest cancers in NSW and our laboratory investigates how this cancer develops. Our focus is the gene encoding p16, which is central to melanoma formation. Individuals with an inherited p16 mutation have increased melanoma-risk. However, while they carry one altered p16 gene, they normally carry a correct second gene from their other parent. The impact of altered p16 on the correct p16 protein remains unclear, and the effect of this “heterozygous” state on melanoma susceptibility is not known. In this study I investigate whether mutant p16 interferes with normal p16 to cause melanoma. Better understanding of this p16 melanoma susceptibility gene product will help to develop urgently needed melanoma therapies.

The Grant was awarded to:

- **Ms Heather McKenzie**

Administering Institute: The University of Sydney

Research Institute: Westmead Millennium Institute

Grant Reference: 07/RSA/1-14

\$25,000 over 1 year

Grant Title: Investigating gonadotropin regulated signalling and effect on microRNA expression in ovarian cancer

Description: Ovarian cancer is the eighth most common cancer in Australian women occurring increasingly after menopause. Its causes are poorly understood, but one of the leading hypotheses states that gonadotropins (follicle-stimulating hormone, FSH and luteinising hormone, LH), which are elevated in postmenopausal women, cause hyperstimulation of ovarian tissue. This project aims to determine the role of gonadotropins in ovarian cancer signal transduction and subsequent gene regulation. Our results show that gonadotropins activate an important signalling pathway in ovarian cancer cells. This signalling process may influence cellular behaviour at the genetic level.

The Grant was awarded to:

- **Miss Inga Mertens**

Administering Institute: The University of Sydney
Research Institute: The University of Sydney

Grant Reference: 07/RSA/1-16

\$25,000 over 1 year

Grant Title: Identification of Molecular Genetic Markers in Pheochromocytomas

Description: Pheochromocytomas and paragangliomas are tumours of the adrenal gland and extra-adrenal tissue, which frequently produce hormones such as adrenaline and noradrenaline. Currently it is difficult for clinicians and pathologists to differentiate benign from malignant pheochromocytomas and so predict the likelihood of cure or recurrence. We aim to look for gene changes that identify whether the pheochromocytoma is benign or malignant, thereby improving current diagnosis, and to look for genes that may be potential targets for the development of novel treatment options, particularly for malignant pheochromocytomas, which currently often have a very poor outlook even with surgical resection.

The Grant was awarded to:

- **Dr Goswin Meyer-Rochow**

Administering Institute: The University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 07/RSA/1-17

\$50,000 over 2 years

Grant Title: Characterisation of the chemopreventative and procarcinogenic effects of the NSAID Sulindac and its relevance to colorectal cancer treatment

Description: This study analyses both the beneficial and harmful effects of Sulindac on the large bowel. Sulindac belongs to a group of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs), which are commonly used to treat inflammatory conditions and also have potential as chemopreventive agents against bowel cancer. My aim is to determine why Sulindac has serious side effects in an experimental mouse model of bowel cancer and how its use could be optimised to eliminate these side effects. This study will lead to a better understanding of how bowel cancer is initiated and to the development of improved cancer prevention strategies.

The Grant was awarded to:

- **Mrs Dessislava Mladenova**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 07/RSA/1-18

\$75,000 over 3 years

Grant Title: The role of PPAR γ and IGFBP-3 interactions in regulating breast cancer

Description: Breast cancer is the leading cause of cancer-related death in Australian women. Breast cancer typically eventuates after normal mammary cells sustain sufficient genetic damage, thus failing to respond to cell regulation. However, breast cancer cells can still respond to a number of proteins, which can affect cell growth. The insulin-like growth factor binding protein-3 (IGFBP-3) and the peroxisome proliferator-activated receptor γ (PPAR γ) have been shown to inhibit the growth of breast cancer cells,

and recent studies have shown that they are binding partners. This project aims to further characterise this interaction and its subsequent cellular consequences on breast cancer cells.

The Grant was awarded to:

- **Miss Cindy Pon**

Administering Institute: The University of Sydney

Research Institute: Kolling Institute of Medical Research

Grant Reference: 07/RSA/1-21

\$50,000 over 1 year

Grant Title: Understanding the role of iron in the anti-tumour activity of iron chelators and delineating the molecular effects of iron depletion

Description: Iron (Fe) binding drugs (chelators) have been merged as promising drugs for cancer therapy. Our aim is to identify the structural features of Fe chelators that lead to anti-proliferative activity and the mechanisms that induce these effects. In particular, it is well known that Fe-depletion results in cell cycle arrest. However, alterations in the expression of molecules involved in cellular proliferation and cell cycle control have not been fully elucidated. This is necessary to examine to understand the marked anti-tumour activity of these compounds. This work is a logical extension of well established studies in our laboratory.

The Grant was awarded to:

- **Ms Federica Saletta**

Administering Institute: The University of Sydney

Research Institute: The University of Sydney

Grant Reference: 07/RSA/1-22

\$62,500 over 2 1/2 years

Grant Title: The role of the tumour suppressor CTCF and its paralogue BORIS in carcinogenesis

Description: An understanding of the way cells control their complex internal circuitry is relevant to diseases like cancer and leukaemia. The main focus of this project is a cellular regulator we identified several years ago called BORIS. Normally dormant in all cells outside the male reproductive organs, BORIS is reactivated in many cancers. We will study the network of factors involved in the inappropriate activation of BORIS in cancer cells. Ultimately this project may lead to new methods of detection and potentially treatments for cancer targeting BORIS or associated factors.

The Grant was awarded to:

- **Miss Jessica Selwyn**

Administering Institute: Centenary Institute of Cancer Medicines and Cell Biology

Research Institute: Centenary Institute of Cancer Medicines and Cell Biology

Grant Reference: 07/RSA/1-24

\$50,000 over 1 year

Grant Title: To characterise the nature and dynamics of long range epigenetic silencing in tumourigenesis through the use of high-resolution technologies

Description: Epigenetics is a term that describes modification of gene expression without a change to the DNA sequence. It is now well established that epigenetics plays a major role in cancer development. Our recent work has uncovered a new way of epigenetic gene silencing that can affect large chromosomal regions, we called "Long Range Epigenetic Silencing" (LRES). In this study we propose to further understand the mechanism involved in LRES and determine its prevalence in cancer. This proposal will shed light onto the process underlying epigenetic gene silencing in cancer and could provide new novel targets for cancer detection and therapy.

The Grant was awarded to:

- **Mr Aaron Statham**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 07/RSA/1-27

\$75,000 over 3 years

Grant Title: Molecular, biochemical and functional analysis of human lymphocyte reconstitution - implications for cancer patients undergoing haematopoietic stem cell transplant

Description: Immunological malignancies in both adults and children can be treated by haematopoietic stem cell transplant (HSCT). Although the cancer survival rate in NSW has increased over the past 2 decades, the overall success of HSCT remains constrained by graft-versus-host disease (GVHD), graft rejection and life-threatening opportunistic infections resulting from the prolonged immunodeficient state in the post-transplant setting. Thus, this project aims to correlate immune cell reconstitution with HSCT outcome, such as GVHD, rejection or successful engraftment. It is anticipated that this project will identify predictors of HSCT outcomes, and will thus allow improved management and treatments of patients with different types of malignancies.

The Grant was awarded to:

- **Miss Santi Suryani**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 07/RSA/1-28

\$50,000 over 1 year

Grant Title: The genetics of inflammation and prostate cancer

Description: A genetic component to prostate cancer risk has been previously established, but to date the genetic events involved in predisposition, initiation and development of this disease is poorly understood. Recent reports have shown an association between symptoms of prostatitis (prostatic inflammation) and sexually transmitted disease with an increased prostate cancer risk. The major focus of my work is to identify variants in genes involved in the body's inflammatory response that may be associated with prostate cancer predisposition and or development, assisting in early diagnosis and treatment.

The Grant was awarded to:

- **Ms Elizabeth Tindall**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 07/RSA/1-30

\$50,000 over 1 year

Grant Title: Novel molecular pathways in colorectal carcinogenesis and their clinical significance

Description: A series of molecular events are required for the development of bowel cancer. The study will examine the role of silenced genes, signalling molecules and inflammatory cytokines believed to be responsible for both malignant tumours and their precursor lesions. This information will be matched with the clinical progress of actual patients for potential practical applications of these markers, including screening, prognosis, relapse risk and/or response to adjuvant chemoradiotherapy.

The Grant was awarded to:

- **Dr Jason Tseung**

Administering Institute: Concord Repatriation General Hospital
Research Institute: Concord Repatriation General Hospital

Grant Reference: 07/RSA/1-31

\$50,000 over 1 year

Grant Title: Development of Novel and Selective Anti-Tumor Agents for the Treatment of Cancer

Description: The search for new drugs with novel mechanisms of action is crucial in improving the prognosis of cancer patients due to emergence of resistance to conventional chemotherapy. Since iron is required for proliferation, tumour cells are markedly more sensitive to iron-deprivation. Hence, iron-depletion is a unique strategy for anti-cancer therapeutics. Recently, we demonstrated that the thiosemicarbazones series of chelators (DpT), showed selective and potent anti-tumour activity *PNAS USA* (Richardson et.al., 4). Hence, we generated another series of chelators based on this series. We will investigate *in vitro* and *in vivo* the anti-tumour activity of these new series of chelators.

The Program Grant was awarded to:

- **Miss Yu Yu**

Administering Institute: The University of Sydney
Research Institute: The University of Sydney

Grant Reference: 07/RSA/1-33

\$50,000 over 1 year

Commencing January 2007

Grant: Characterization of protein binding partners and genomic target sites of Elf5, a novel gene involved in mammary gland development.

The Grant was awarded to:

- **Ms Maria Kalyuga**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 06/RSA/1-11

\$75,000 over 3 years

Grant: Defining the role of BAG-1 in the apoptotic response of breast cancer cells to antiestrogens.

The Grant was awarded to:

- **Mr Luke Anderson**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 06/RSA/1-02

\$75,000 over 3 years

Grant: Retinoids as potential therapeutics in Pancreatic Cancer.

The Grant was awarded to:

- **Miss Johana Susanto**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 06/RSA/1-25

\$75,000 over 3 years

Grant: Methods for integrating quality of life data to improve evidence-based decision-making about cancer treatments.

The Grant was awarded to:

- **Dr Peter Grimison**

Administering Institute: The University of Sydney

Research Institute: The University of Sydney

Grant Reference: 06/RSA/1-10

\$50,000 over 2 years

Grant: Interplay of inflammatory mediators, nuclear receptors and myogenic factors in Cancer Cachexia Syndrome (CCS).

The Grant was awarded to:

- **Mr Anthony Corradin**

Administering Institute: University of New South Wales
Research Institute: University of New South Wales

Grant Reference: 06/RSA/1-06

\$75,000 over 3 years

Grant: Cancer in people with primary, acquired and iatrogenic immunodeficiency.

The Grant was awarded to:

- **Ms Marina van Leeuwen**

Administering Institute: University of New South Wales
Research Institute: University of New South Wales

Grant Reference: 06/RSA/1-28

\$50,000 over 2 years

Grant: Investigation into the Pathogenesis of Pituitary Tumours.

The Grant was awarded to:

- **Dr Marianne Elston**

Administering Institute: University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 06/RSA/1-09

\$50,000 over 2 years

Grant: The role of defective apoptosis pathways in drug resistance of malignant melanoma.

The Grant was awarded to:

- **Miss Keryn Lucas**

Administering Institute: The Centenary Institute
Research Institute: The Centenary Institute

Grant Reference: 06/RSA/1-15

\$25,000 over 1 year

Grant: The molecular functions of the metastasis suppressor Ndrp-1 and its potential role in the treatment of cancer.

The Grant was awarded to:

- **Miss Zaklina Kovacevic**

Administering Institute: University of Sydney

Research Institute: University of Sydney

Grant Reference: 06/RSA/1-12

\$75,000 over 3 years

Grant: Retinoic Acid Signalling in Pancreatic cancer.

The Grant was awarded to:

- **Miss Emily Colvin**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 06/RSA/1-05

\$75,000 over 3 years

Grant: The role of Hedgehog signalling in the development and progression of breast cancer.

The Grant was awarded to:

- **Dr Sandra Biankin**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 06/RSA/1-03

\$50,000 over 2 years

Grant: Expression of tumor protein D52 and related proteins, and the regulation of mitosis.

The Grant was awarded to:

- **Mr Keerthi Thamocharampillai**

Administering Institute: University of Sydney

Research Institute: The Children's Hospital at Westmead

Grant Reference: 06/RSA/1-26

\$50,000 over 2 years

Grant: Radiation induced prostate gland volume changes and tissue biomechanical properties as observed with magnetic resonance imaging (MRI).

The Grant was awarded to:

- **Ms Michala Rybovic**

Administering Institute: University of Sydney

Research Institute: Royal North shore Hospital and the Brain and Mind Research Institute

Grant Reference: 06/RSA/1-21

\$50,000 over 1 year

Grant: The role of serine/threonine protein phosphatases in breast cancer.

The Grant was awarded to:

- **Miss Lauren Cottrell**

Administering Institute: University of Newcastle

Research Institute: University of Newcastle

Grant Reference: 06/RSA/1-07

\$75,000 over 3 years

Commencing July 2005

Grant: The role of PPAR gamma in thyroid malignancy

The Grant was awarded to:

- **Amy Au**

Administering Institute: Kolling Institute of Medical Research

Research Institute: Kolling Institute of Medical Research

Grant Reference: 05/RSA/1-01

\$25,000 over 1 year

Grant: The role of Id-1 in normal proliferation and transformation of mammary epithelial cells

The Grant was awarded to:

- **Catherine (Liz) Caldon**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 05/RSA/1-25

\$50,000 over 2 years

Grant: Investigation of the role of the tumour suppressor gene PTEN in overgrowth and tumour development

The Grant was awarded to:

- **Wey Yeeng Chee**

Administering Institute: University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 05/RSA/1-13

\$75,000 over 3 years

Grant: Mechanism of tissue factor activation

The Grant was awarded to:

- **Dr Vivien Chen**

Administering Institute: University of New South Wales
Research Institute: University of New South Wales

Grant Reference: 05/RSA/1-07

\$75,000 over 3 years

Grant: DNA repair, oncogenesis and mechanism of antibody hyper mutation

The Grant was awarded to:

- **Adam Cook**

Administering Institute: Centenary Institute of Cancer Medicine and Cell Biology
Research Institute: Centenary Institute of Cancer Medicine and Cell Biology

Grant Reference: 05/RSA/1-11

\$43,750 over 1.5 years

Grant: Survival signalling in cancer

The Grant was awarded to:

- **Lauren Cowell**

Administering Institute: University of Sydney
Research Institute: The Children's Hospital at Westmead

Grant Reference: 05/RSA/1-05

\$50,000 over 2 years

Grant: Mechanisms underlying synergy between SDF-1 and IL-7 in acute lymphoblastic leukaemia

The Grant was awarded to:

- **Shivanshni Gaunder**

Administering Institute: University of Sydney

Research Institute: Westmead Millennium Institute

Grant Reference: 05/RSA/1-14

\$75,000 over 3 years

Grant: A strategy to improve informed consent: a randomised trial in patients undergoing colonoscopy

The Grant was awarded to:

- **Haryana Dhillon**

Administering Institute: University of Sydney

Research Institute: University of Sydney

Grant Reference: 05/RSA/1-15

\$75,000 over 3 years

Grant: Mechanisms of photo protection by 1,25-dihydroxyvitamin D3

The Grant was awarded to:

- **Katie Dixon**

Administering Institute: University of Sydney

Research Institute: University of Sydney

Grant Reference: 05/RSA/1-16

\$50,000 over 2 years

Grant: Microarray analysis of human B-cell subsets to identify key regulators of lymphocyte differentiation: implications for B-cell malignancy

The Grant was awarded to:

- **Kim Lee Good**

Administering Institute: Centenary Institute of Cancer Medicine and Cell Biology

Research Institute: Centenary Institute of Cancer Medicine and Cell Biology

Grant Reference: 05/RSA/1-10

\$25,000 over 1 year

Grant: Cannabionoids and cancer: anti-proliferative effects and MDR modulating actions

The Grant was awarded to:

- **Michelle Holland**

Administering Institute: University of Sydney

Research Institute: University of Sydney

Grant Reference: 05/RSA/1-19

\$50,000 over 2 years

Grant: The role of bone marrow-derived factors on the survival of normal and leukemic B-cell progenitors

The Grant was awarded to:

- **Naveed Khan**

Administering Institute: University of Sydney

Research Institute: Westmead Millennium Institute

Grant Reference: 05/RSA/1-22

\$50,000 over 2 years

Grant: The role of bone marrow-derived factors on the survival of normal and leukemic B-cell progenitors (2 years) A non-human primate model of stem cell mobilisation, transplantation and gene therapy

The Grant was awarded to:

- **Dr Stephen Larsen**

Administering Institute: Centenary Institute of Cancer Medicine and Cell Biology

Research Institute: Centenary Institute of Cancer Medicine and Cell Biology

Grant Reference: 05/RSA/1-12

\$25,000 over 1 year

Grant: Proteomic profiling of serum and cyst fluid to improve the diagnosis of pancreatic Aden carcinoma and cystic lesions using surface-enhanced laser desorption ionisation time-of-flight mass spectroscopy (SELDI-TOF MS)

The Grant was awarded to:

- **Christopher Scarlett**

Administering Institute: University of Sydney

Research Institute: Royal North Shore Hospital

Grant Reference: 05/RSA/1-08

\$50,000 over 2 years

Grant: Genetic factors involved in the tumour genesis of adrenocortical tumours

The Grant was awarded to:

- **Dr Patsy Soon**

Administering Institute: Kolling Institute of Medical Research

Research Institute: Kolling Institute of Medical Research

Grant Reference: 05/RSA/1-02

\$75,000 over 3 years

Grant: CGH array analysis of childhood cancers

The Grant was awarded to:

- **Bente Talseth**

Administering Institute: University of Newcastle

Research Institute: Hunter Medical Research Institute

Grant Reference: 05/RSA/1-04

\$75,000 over 3 years

Commencing January 2006

Grant: The p14ARF melanoma tumour suppressor promotes chemo sensitivity

The Grant was awarded to:

- **Stuart Gallagher**

Administering Institute: University of Sydney

Research Institute: Westmead Millennium Institute

Grant Reference: 05/RSA/2-05

\$25,000 over 1 year

Grant: Signalling pathways in endometrial cancer

The Grant was awarded to:

- **Lujia Gribben**

Administering Institute: University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 05/RSA/2-06

\$75,000 over 3 years

Grant: Regulation of multidrug transporter expression by MYC-family oncogenes

The Grant was awarded to:

- **Lye Lin Ho**

Administering Institute: University of Sydney
Research Institute: Centenary Institute

Grant Reference: 05/RSA/2-08

\$50,000 over 2 years

Grant: End-of-life decision-making: A randomized controlled trial of a structured intervention for patients with advanced cancer

The Grant was awarded to:

- **Rhea Stein**

Administering Institute: University of Sydney
Research Institute: The Mater Hospital, Concord Repatriation General Hospital and Royal Prince Alfred Hospital

Grant Reference: 05/RSA/2-14

\$25,000 over 1 year

Grant: Quality of life and arm symptoms following axillary surgery for breast cancer

The Grant was awarded to:

- **Dr Michella Smith**

Administering Institute: University of Sydney
Research Institute: University of Sydney

Grant Reference: 05/RSA/2-16

\$75,000 over 3 years

Grant: Chemotherapy and high grade glioma: Genetic studies

The Grant was awarded to:

- **Dr Jonathon Parkinson**

Administering Institute: University of Sydney
Research Institute: Kolling Institute of Medical Research

Grant Reference: 05/RSA/2-17

\$50,000 over 2 years

Grant: The role of protein phosphatase 2A in cancer

The Grant was awarded to:

- **Ms Kathryn Roberts**

Administering Institute: University of Newcastle
Research Institute: University of Newcastle

Grant Reference: 05/RSA/2-19

\$75,000 over 3 years

Grant: The role of microRNA in the development and progression of breast cancer

The Grant was awarded to:

- **Mr Alex Shaw**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 05/RSA/2-24

\$75,000 over 3 years

Grant: Epigenetic changes in breast cancer

The Grant was awarded to:

- **Ms Rebecca Hinshelwood**

Administering Institute: Garvan Institute of Medical Research
Research Institute: Garvan Institute of Medical Research

Grant Reference: 05/RSA/2-25

\$50,000 over 2 years

Grant: The role of XBP1 and the unfolded protein and endoplasmic reticulum stress responses in mediating drug resistance in multiple myeloma

The Grant was awarded to:

- **Dr Sylvia Ling**

Administering Institute: Centenary Institute of Cancer Medicine and Cell Biology
Research Institute: Centenary Institute of Cancer Medicine and Cell Biology

Grant Reference: 05/RSA/2-28

\$50,000 over 2 years

Commencing January 2005

Grant: Impact of DNA damage and breast cancer mutations on BRCA1 nuclear localisation and focus formation

The Grant was awarded to:

- **Wendy Au**

Administering Institute: University of Sydney
Research Institute: University of Sydney

Grant Reference: 04/RSA/1-02

\$25,000 over 1 year

Grant: PAI-2 cancer therapy: shrinking the magic bullet

The Grant was awarded to:

- **David Croucher**

Administering Institute: University of Wollongong
Research Institute: University of Wollongong

Grant Reference: 04/RSA/1-04

\$25,000 over 1 year

Grant: The relationship between physical activity, anthropometry and cancer risk: epidemiology and methodological issues

The Grant was awarded to:

- **Anne Cust**

Administering Institute: University of Sydney
Research Institute: University of Sydney

Grant Reference: 04/RSA/1-05

\$75,000 over 3 years

Grant: Communicating information to women about diagnostic tests to investigate a breast symptom

The Grant was awarded to:

- **Heather Davey**

Administering Institute: University of Sydney

Research Institute: University of Sydney

Grant Reference: 04/RSA/1-06

\$25,000 over 1 year

Grant: Oestrogen target genes and endocrine resistance in breast cancer

The Grant was awarded to:

- **Dr Catriona McNeil**

Administering Institute: Garvan Institute of Medical Research

Research Institute: Garvan Institute of Medical Research

Grant Reference: 04/RSA/1-18

\$75,000 over 3 years

Grant: Genomic and proteomic study of ovarian cancer

The Grant was awarded to:

- **Michelle Moscova**

Administering Institute: University of Sydney

Research Institute: Kolling Institute of Medical Research

Grant Reference: 04/RSA/1-19

\$50,000 over 2 years

Grant: Regulation of nuclear hormone receptor-signalling by insulin-like growth factor binding proteins in breast cancer

The Grant was awarded to:

Michelle O'Han

Administering Institute: University of Sydney

Research Institute: Kolling Institute of Medical Research

Grant Reference: 04/RSA/1-20

\$50,000 over 2 years

Grant: How to cope with the worst but hope for the best: cognitive behaviour therapy for children and adolescents with leukaemia

The Grant was awarded to:

- **Michelle Pritchard**

Administering Institute: University of Sydney

Research Institute: University of Sydney, The Children's Hospital at Westmead, Sydney Children's Hospital Randwick and Mater Hospital Brisbane.

Grant Reference: 04/RSA/1-21

\$25,000 over 1 year

Grant: Drug metabolism and inflammation in malignancy

The Grant was awarded to:

- **Dr Rohini Sharma**

Administering Institute: University of Sydney

Research Institute: Westmead Millennium Institute

Grant Reference: 04/RSA/1-24

\$50,000 over 2 years

Grant: Determination of diagnostic molecular profiles for intraduct lesions of the breast

The Grant was awarded to:

- **Lucy Webster**

Administering Institute: University of Sydney

Research Institute: Westmead Millennium Institute, University of Sydney

Grant Reference: 04/RSA/1-32

\$25,000 over 1 year
